Close menu

January 12th, 2022 | 13:42 CET

Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?

  • Biotechnology
Photo credits:

Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    Bayer - Pharma sector is promising

    Bayer almost became a vaccine manufacturer, but the efficacy of the CureVac vaccine was not high enough, and so Bayer did not even go into production. Bayer's focus is still on the risks from the Monsanto acquisition. A capital investor test case was recently added, which does not involve a risk of EUR 1 billion as was initially the case, but even up to EUR 2.2 billion. But the good news from the pharmaceutical sector did not help the share.

    Last December alone, the Group reported three positive announcements. At the beginning of December, encouraging results came out of Phase III Arasens study, according to which patients with metastatic prostate cancer can live significantly longer. On December 17, Finerenon, a drug for chronic kidney disease and diabetes, was recommended for EU approval. The final step was the approval of Xarelto by the FDA in the US on December 21. The drug is an anticoagulant and was approved for two additional use cases in children.

    The majority of analysts now recommend buying the share. Price targets between EUR 58 and EUR 85 are issued. The share formed an initial upward trend on January 4 and is currently trading at EUR 50.92. The share price is expected to rise above this level by the end of the year. Closing prices above EUR 51.84 would break the downward trend. After the decent increase in the last few days, the dividend yield at the current share price has fallen back to just below 4%.

    XPhyto Therapeutics - Clinical study on epilepsy

    There has been a lot going on at Canadian biotech company XPhyto Therapeutics over the past month and a half. To kick things off on November 26, the Company raised a total of CAD 7 million. The money was used on December 6 to finalize the acquisition of 3a-diagnostics GmbH (3a), the partner it co-developed the rapid PCR test with. The acquisition strengthened the diagnostics business area, as 3a is considered a specialist in biosensor development. A detailed analysis of the business units can be viewed at

    Conventional antigen tests detect Corona only at elevated viral loads, so sufferers may receive a negative test. The developed 25min PCR test achieves more accuracy and does so almost as quickly as an antigen test. In addition, the tests can be performed directly on-site without a laboratory, making them ideal for point-of-care facilities at the airport, pharmacies, etc. According to Allied Market Research, the market is expected to grow to USD 39 billion by 2023. On December 15, the Company announced that it would begin an epilepsy clinical trial with soluble oral CBD strips in 2022. If the pilot study is successful, a pivotal study will follow in H2 2022.

    On January 10, a director of business development, Roland Spleiss, was hired. He has already proven at Wörwag Pharma (200 million sales) that he can drive the internationalization of companies and optimize supply chains and sales processes. Dr. Heinrich Jehle, a top-class expert, was recruited for the Diagnostics Division. The share has run sideways between CAD 1.05 and CAD 1.28 since mid-November. From this perspective, the latest news has had no effect. If the Company succeeds in landing a major order for PCR tests, the share price should pick up quickly.

    MorphoSys - New lows again

    The biotech company MorphoSys was once a model company from Germany. The problems started when the founder wanted to transform the contract research organization into a pharmaceutical company. Many areas, such as sales and distribution, were simply underestimated. MorphoSys has been paying the price ever since. The Company, which says it wants to give people with cancer a better and longer life, has made a mess by acquiring Constellation Pharmaceuticals for EUR 1.5 billion.

    Hopes rest on pelabresib, a drug used in bone marrow cancer currently in a phase 3 trial. In the latest update on the drug on December 12, Peters, the Company's chief research and development officer, said, "These data confirm previously published results and reinforce the importance that pelabresib could have in the difficult treatment of myelofibrosis if approved." The second major hopeful, Monjuvi, which is co-marketed with Incyte in the US, fell short of lofty expectations. In 2021, sales were expected to be around USD 79 million. In 2022, however, sales are expected to climb to between USD 110 million and USD 135 million.

    Sales have fallen short of expectations, research costs will more than double in 2022, and much of the licensing revenue will go to the backer for the Constellation acquisition. No wonder the stock has already hit new lows of EUR 28.11 this year. At the current price of EUR 32.17, the market capitalization is only EUR 1.1 billion, 400 million less than was paid for the acquisition alone. When the approval of pelabresib comes, the world will look different again, but until then, one should wait for the break of the downward trend.

    A lot is going on in the pharmaceutical and biotech sector. While Bayer is still suffering from the Monsanto takeover, things are already improving in the pharmaceutical sector. XPhyto has recently repositioned itself through the acquisition and the newly acquired personnel. The potential must now be developed. At MorphoSys, a lot depends on the funds from Constellation. If the approvals come through, the turnaround will succeed.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Fabian Lorenz on May 19th, 2022 | 13:31 CEST

    Booster for the BioNTech share: BASF and Defense Metals with momentum?

    • RareEarths
    • Biotechnology

    The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.


    Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

    Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

    • Biotechnology
    • Covid19

    For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?


    Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

    Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

    • Biotechnology

    No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...